biotech · Acute Respiratory Distress Syndrome (ARDS) · Allergic Contact Dermatitis · EDSA
Edesa Biotech
Edesa Biotech is a biotech organization headquartered in Markham, CA. It trades on NYSE under ticker EDSA. Primary therapeutic focus areas include Acute Respiratory Distress Syndrome (ARDS), Allergic Contact Dermatitis,
Markham, CA HQ
2015 Founded
22 Employees
Public company Type
EDSA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Markham, CA
- Founded
- 2015
- Employees
- 22
- Programs
- 5
- Drugs
- 5
- Patents
- 0
EB01 Cream Placebo
Phase 2 · small molecule · Allergic Contact Dermatitis
EB01 Cream Placebo for Allergic Contact Dermatitis is a Phase 2 program (small_molecule) at Edesa Biotech with 1 ClinicalTrials.gov record(s).
Internal code EB01-01-2018
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Edesa Biotech
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Allergic Contact Dermatitis
- Status
- completed
- Trials
- 1